Skip to main content
. 2021 Apr 29;65(4):411–420. doi: 10.20945/2359-3997000000364

Table 3. Adverse events during MKI treatment.

Any grade G1-G2 (%) G3-G4 (%)
Hand-foot syndrome 30 22 (50) 8 (18.2)
Diarrhea 31 25 (56.8) 6 (13.6)
Fatigue 31 29 (65.9) 2 (4.6)
Hypertension 5 4 (9.0) 1 (2.3)
Alopecia 11 9 (20.4) 3 (6.8)
Anorexia 5 5 (11.3) 0
Weight loss 8 8 (18.2) 0
Nausea 9 8 (18.2) 1 (2.3)
Rash 7 5 (11.3) 2 (4.6)
Hematologic toxicity 1 1 (2.3) 0
Pruritus 1 1 (2.3) 0
Secondary neoplasia 1 0 1 (2.3)

MKI: multikinase inhibitors.